https://orcid.org/0000-0001-5310-5947
References
- Madhu PM, Alina N, Hillary M, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39:1719–1729.
- Zain JM. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(8):929–946.
- Chihara D, Fanale MA, Miranda RN, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLOS One. 2018;13(3):e0191461.
- Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish lymphoma registry study. Blood. 2015;126(1):36–41.
- Nozaki K, Yokota T, Itotagawa E, et al. Whole-exome sequencing identified mutational profile of a case with T-cell chronic lymphocytic leukemia. Clin Case Rep. 2020;8(11):2251–2254.
- Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.
- Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):565–577.
- Robak T, Korycka A, Ewa LM, et al. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules. 2009;14(3):1183–1226.
- Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor – BCX-1777. Int Immunopharmacol. 2003;3(6):879–887.